Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Binbin Xuan"'
Publikováno v:
PLoS ONE, Vol 12, Iss 3, p e0175005 (2017)
[This corrects the article DOI: 10.1371/journal.pone.0170630.].
Externí odkaz:
https://doaj.org/article/657bd42a1acd4dc9b909030a56e77aa7
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170630 (2017)
Drug resistance constitutes one of the main obstacles for clinical recovery of acute myeloid leukemia (AML) patients. Therefore, the treatment of AML requires new strategies, such as adding a third drug. To address whether GATA2 could act as a regula
Externí odkaz:
https://doaj.org/article/538bd8fad3ad46c0ba8c5f818c8dca50
Autor:
Haiyan Zhang, Jian-Jun Zou, Yubing Zhu, Binbin Xuan, Liyan Miao, Meiqin Lin, Wenfang Zhuang, Hanfan Qiu, Ling Zhou, Hongtao Song, Zhenya Shen, Cheng Xie, Linsheng Liu, Yanhong Chen, Yingchao Fan, Lianhong Xu, Yuzhen Zhang, Junrong Zhu, Ling Xue, Di Wu
Publikováno v:
European Journal of Clinical Pharmacology. 75:785-794
The objectives of the study were to establish a dose–response model for warfarin based on the relationship between daily warfarin dose and international normalized ratio (INR) and to evaluate the stability and reliability of the established model u
Autor:
Binbin Xuan, Xiaoliang Wang
Publikováno v:
Journal of Bionic Engineering. 13:468-477
The bionic propulsion can be used on the aerostat and other automatic vehicles. The general single oscillating tail fin can induce the yawing and whole airship rolling because of the lateral force and the gravity moment of heavier oscillating tail fi
Publikováno v:
Blood Coagulation & Fibrinolysis. 26:167-174
In this study, we studied the effects of different genetic variants of CYP2C9, VKORC1 and CYP4F2, and clinical factors on the concentration levels of S-warfarin (WF), R-WF and S, R-7-OH-WF, as well as the mean daily maintenance dose of warfarin in 21
Publikováno v:
PLoS ONE, Vol 12, Iss 3, p e0175005 (2017)
PLoS ONE
PLoS ONE
Drug resistance constitutes one of the main obstacles for clinical recovery of acute myeloid leukemia (AML) patients. Therefore, the treatment of AML requires new strategies, such as adding a third drug. To address whether GATA2 could act as a regula
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 1, p e0170630 (2017)
PLoS ONE, Vol 12, Iss 1, p e0170630 (2017)
Drug resistance constitutes one of the main obstacles for clinical recovery of acute myeloid leukemia (AML) patients. Therefore, the treatment of AML requires new strategies, such as adding a third drug. To address whether GATA2 could act as a regula
Publikováno v:
Blood Coagulation & Fibrinolysis; Mar2015, Vol. 26 Issue 2, p167-174, 8p